Six-month decline of serum anti-spike S1 subunit IgA in SARS-CoV-2 in seronegative healthcare workers after mRNA-based COVID-19 vaccination

Abstract Background: Since serum anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) IgA antibodies correlate with secretory anti-SARS-CoV-2 IgA and contribute to virus neutralization, we planned an observational study to measure serum anti-SARS-CoV-2 IgAs kinetics throughout a 6-month period in coronavirus disease 2019 (COVID-19) vaccine recipients.Methods: The study sample consisted of 97 baseline SARS-CoV-2 seronegative healthcare workers (median age 42 years and IQR 31-52 years; 52 females), who underwent vaccination with Pfizer/BioNTech Comirnaty mRNA-based vaccine (two 30 µg doses, 21 days apart). Serum samples were collected at baseline, before the second vaccine dose (i.e., day 21), and then 51, 111 and 201 days after enrolment (i.e., 1, 3 and 6 months after the second vaccine dose). Serum anti-SARS-CoV-2 spike S1 subunit IgA were measured with Anti-SARS-CoV-2 ELISA IgA (Euroimmun, Lübeck, Germany).Results: Anti-SARS-CoV-2 spike S1 subunit IgA displayed a peak at 1 month after the second vaccine dose, but then progressively waned afterwards. The 6-month serum anti-spike S1 subunit IgA concentration was 71% lower than the peak concentration. The rate of subjects with positive IgA values was 0% at baseline, 80.4% at day 21, 97.9% at day 51, but then declined to 73.2% and 53.6% at 3 and 6 months after the second vaccine dose. Serum anti-spike S1 subunit IgAs measured at 111 and 201 days was significantly lower than at the 51-day peak (both p<0.001). Significant inverse correlation was found between anti-SARS-CoV-2 IgA antibodies decline at 6 months/ and recipients’ age (r=-0.24; p=0.019).Conclusion: These findings may provide possible explanation to decreased efficacy of COVID-19 vaccines in preventing SARS-CoV-2 infection 6 months after vaccination.

Download Full-text

COMPARISON OF PERFORMANCE CHARACTERISTICS BETWEEN LATERAL FLOW, ELISA AND ELECTROCHEMILUMINESCENCE IMMUNOASSAYS FOR THE DETECTION OF SARS-COV-2 ANTIBODIES AMONG HEALTHCARE WORKERS

10.1101/2021.04.29.21256260 ◽

2021 ◽

Author(s):

M R Shincy ◽

Vandana Govindan ◽

H H Sudhakar ◽

V T Venkatesha ◽

K Padmapriya ◽

...

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Healthcare Workers ◽

Care Pathway ◽

Point Of Care ◽

Lateral Flow ◽

Central Research ◽

Serum Samples ◽

Igg Antibody ◽

Human Igg ◽

Serological Tests

ABSTRACTBackgroundMedical professionals and researchers have been urging the need for wide and rapid testing of citizens in order to plan measures that can contain the spread of the virus. Antibody tests play an important role throughout the patient care pathway and are vital for the management and surveillance of the virus. Although RT-PCR is considered as the gold standard, serological tests based on antibodies are helpful for on-time detection. We performed one to one assessment of point-of-care lateral flow assay (POCTs), enzyme immunoassay (EIAs), electrochemiluminescence immunoassay (CLIA), to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG antibody.Materials and Methods611 healthcare workers were recruited between November and December 2020 at Central Research Laboratory, KIMS. Collected serum samples were analysed according to manufacturer’s protocol. The Standard Q IgG/IgM combo assay, Anti-SARS CoV-2 Human IgG ELISA, and the Elecsys® to measure the IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).ResultsThe kits displayed a sensitivity of 61.2%,79.5%, 91.8% and specificity of 61.7%,64.1%,80.2% for the Standard Q IgG/IgM combo assay, Anti-SARS CoV-2 Human IgG ELISA, and the Elecsys® in order.ConclusionOur results indicate high sensitivity and specificity for the Elecsys® assay compared to Anti-SARS CoV-2 Human IgG ELISA, the Standard Q IgG/IgM combo assay.

Download Full-text

The pronounced decline of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG in baseline seronegative individuals 6 months after BNT162b2 vaccination is consistent with the need for vaccine boosters

10.21203/rs.3.rs-1063499/v1 ◽

2021 ◽

Author(s):

Gian Luca Salvagno ◽

Brandon M. Henry ◽

Laura Pighi ◽

Simone De Nitto ◽

Gianluca Gianfilippi ◽

...

Keyword(s):

Retrospective Study ◽

Severe Acute Respiratory Syndrome ◽

Observational Study ◽

Vaccine Dose ◽

Serum Levels ◽

Receptor Binding Domain ◽

Igg Antibodies ◽

Kinetics Of ◽

Timely Administration ◽

Median Rate

Abstract Background: This observational retrospective study aimed to define the kinetics of serum levels of anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike trimeric and anti-receptor binding domain (RBD) IgG antibodies up to 6 months after BNT162b2 vaccination. Methods: The sample consisted of 86 SARS-CoV-2 baseline seronegative subjects (median age 45 years, IQR 31-53 years; 52.3% females) undergoing vaccination with Pfizer/BioNTech BNT162b2. Blood was drawn before receiving the first and the second vaccine dose, as well as 1, 3 and 6 months after the second vaccine dose. The serum levels of anti-SARS-CoV-2 spike trimeric IgG and RBD IgG antibodies were assayed.Results: The peak of both antibodies types was reached 1 month after the second dose (2808 and 2163 BAU/mL for anti-SARS-CoV-2 spike trimeric IgG and RBD IgG), after which serum levels progressively declined, falling after 6 months to 486 BAU/mL and 167 BAU/mL for anti-SARS-CoV-2 spike trimeric IgG and RBD IgG, respectively. The median rate of 6-month decline was 85% and 93% for anti-SARS-CoV-2 spike trimeric IgG and RBD IgG, respectively. The rate of vaccine recipients with serum antibodies levels above the 80% threshold of vaccine efficacy declined from over 95% at the peak to 72% and 5% at 6 months for anti-SARS-CoV-2 spike trimeric IgG and RBD IgG, respectively.Conclusions: The results of this retrospective observational study are consistent with the need for timely administration of vaccine boosters to prevent that humoral immunity will wane.

Download Full-text

Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers

Journal of Medical Biochemistry ◽

10.5937/jomb0-32373 ◽

2021 ◽

Author(s):

Gian Luca Salvagno ◽

Brandon Henry ◽

Giovanni Di Piazza ◽

Laura Pighi ◽

Simone De Nitto ◽

...

Keyword(s):

Neutralizing Antibodies ◽

Healthcare Workers ◽

Vaccine Dose ◽

Serum Levels ◽

Cell Mediated Immunity ◽

Inverse Association ◽

Serum Samples ◽

Serum Igg ◽

Study Population

Background: Most studies on immune response after coronavirus disease 2019 (COVID-19) vaccination focused on serum IgG antibodies and cell-mediated immunity, discounting the role of anti-SARS-CoV-2 neutralizing IgA antibodies in preventing viral infection. This study was aimed to quantify serum IgG and IgA neutralizing antibodies after mRNA COVID-19 vaccination in baseline SARS-CoV-2 seronegative healthcare workers. Methods: The study population consisted of 181 SARS-CoV-2 seronegative healthcare workers (median age 42 years, 59.7% women), receiving two doses of Pfizer COVID-19 vaccine BNT162b2. Serum samples were collected before receiving the first vaccine dose, 21 days (before the second vaccine dose) and 50 days afterwards. We then measured anti-spike trimeric IgG (Liaison XL, DiaSorin), anti-spike receptor binding domain (RBD) IgG (Access 2, Beckman Coulter) and anti-spike S1 subunit IgA (ELISA, Euroimmun). Results were presented as median and interquartile range (IQR). Results: Vaccine administration elicited all anti-SARS-CoV-2 antibodies measured. Thirty days after the second vaccine dose, 100% positivization occurred for anti-spike trimeric IgG and anti-spike RBD IgG, whilst 1.7% subjects remained anti-spike S1 IgA negative. The overall increase of antibodies level over baseline after the second vaccine dose was 576.1 (IQR, 360.7-867.8) for anti-spike trimeric IgG, 1426.0 (IQR, 742.0-2698.6) for anti-spike RBD IgG, and 20.2 (IQR, 12.5-32.1) for anti-spike S1 IgA. Significant inverse association was found between age and overall increase of anti-spike trimeric IgG (r=-0.24; p=0.001) and anti-spike S1 IgA (r=-0.16; p=0.028), but not with anti-spike RBD IgG (r=-0.05; p=0.497). Conclusions: mRNA COVID-19 vaccination elicits sustained serum levels serum anti-spike trimeric IgG and anti-spike RBD IgG, while also modestly but significantly increasing those of serum anti-spike S1 IgA.

Download Full-text

COMPARISON OF PERFORMANCE CHARACTERISTICS BETWEEN LATERAL FLOW, ELISAAND ELECTROCHEMILUMINESCENCE IMMUNOASSAYS FOR THE DETECTION OF SARS-COV-2 ANTIBODIES AMONG HEALTHCARE WORKERS

10.36106/ijsr/0101617 ◽

2021 ◽

pp. 45-48

Author(s):

Shincy M R ◽

Vandana Govindan ◽

Sudhakar H H ◽

Padmapriya K ◽

Venkatesha V T ◽

...

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Healthcare Workers ◽

Care Pathway ◽

Point Of Care ◽

High Sensitivity ◽

Central Research ◽

Serum Samples ◽

Igg Antibody ◽

Human Igg ◽

Serological Tests

Background: The detection of SARS-CoV-2 IgG is important to determine the course of COVID-19. Medical professionals and researchers have been urging the need for wide and rapid testing of citizens in order to plan measures that can contain the spread of the virus. Antibody tests play an important role throughout the patient care pathway and are vital for the management and surveillance of the virus. Although RTPCR is considered to be the gold standard, serological tests based on antibodies could be very helpful for on-time detection. We performed one to one assessment of electrochemiluminescence immunoassay, enzyme immunoassay (EIAs), and point-of-care lateral ow assay (POCTs) to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG antibody. Materials and Methods: 611 healthcare workers were recruited between November and December 2020 at Central Research Laboratory, KIMS. ® Collected serum samples were analysed using three commercially available assays: the Elecsys , Anti-SARS CoV-2 Human IgG ELISA, the Standard Q IgG/IgM combo assay following the manufacturer's protocol to measure the IgG titer of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Results:The kits displayed a sensitivity of 91.8%, 79.5% ,61.2% and a specicity of 80.2%, 64.1% ,61.7% in order. Conclusion: ® Our results indicate a high sensitivity and specicity for the Elecsys assay compared to Anti-SARS CoV-2 Human IgG ELISA, the Standard Q IgG/IgM combo assays.

Download Full-text

Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days

The Journal of Infectious Diseases ◽

10.1093/infdis/jiab140 ◽

2021 ◽

Author(s):

Amanda Haymond ◽

Abdulla A Damluji ◽

Aarthi Narayanan ◽

Claudius Mueller ◽

Alex Reeder ◽

...

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Receptor Binding ◽

Immunoglobulin G ◽

Neutralizing Antibodies ◽

Healthcare Workers ◽

Binding Domain ◽

Receptor Binding Domain ◽

Serum Samples ◽

Viral Neutralization ◽

Time Period

Abstract A cohort consisting of asymptomatic healthcare workers donated temporal serum samples after infection with severe acute respiratory syndrome coronavirus 2. Analysis shows that all asymptomatic healthcare workers had neutralizing antibodies, that these antibodies persist for ≥60 days, and that anti-spike receptor-binding domain immunoglobulin G levels were correspondingly durable over the same time period.

Download Full-text

Seroprevalence of SARS-CoV-2 Antibodies Among Rural Healthcare Workers

10.1101/2021.06.07.21258375 ◽

2021 ◽

Author(s):

Jordan Z Neises ◽

Hossain Md Saddam ◽

Rifat Sultana ◽

Kevin N Wanniarachchi ◽

Jared W Wollman ◽

...

Keyword(s):

South Dakota ◽

Healthcare Workers ◽

Virus Neutralization ◽

Serum Samples ◽

Public Health Agencies ◽

Fluorescent Microsphere ◽

Previous Diagnosis ◽

Health Agencies ◽

Study Population ◽

Microsphere Immunoassay

The objective of this longitudinal cohort study was to determine the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in healthcare workers employed at healthcare clinics in three rural counties in eastern South Dakota and western Minnesota from May 13, 2020 through December 22, 2020. Three blood draws were performed at five clinical sites and tested for the presence of antibodies against the SARS-CoV-2 virus. Serum samples were tested for the presence of antibodies using a fluorescent microsphere immunoassay (FMIA), neutralization of SARS-CoV-2 Spike-pseudotyped particles (SARS-CoV-2pp) assay, and serum virus neutralization (SVN) assay. The seroprevalence was determined to be 1/336 (0.29%) for samples collected from 5/13/20-7/13/20, 5/260 (1.92%) for samples collected from 8/13/20-9/25/20, and 35/235 (14.89%) for samples collected from 10/16/20-12/22/20. Eight of the 35 (22.8%) seropositive individuals identified in the final draw did not report a previous diagnosis with COVID-19. There was a high correlation (>90%) among the FMIA and virus neutralization assays. Each clinical site's seroprevalence was higher than the cumulative incidence for the general public in each respective county as reported by state public health agencies. As of December 2020, there was a high percentage (85%) of seronegative individuals in the study population.

Download Full-text

Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer

Diagnostics ◽

10.3390/diagnostics12010085 ◽

2021 ◽

Vol 12 (1) ◽

pp. 85

Author(s):

Seri Jeong ◽

Nuri Lee ◽

Su-Kyung Lee ◽

Eun-Jung Cho ◽

Jungwon Hyun ◽

...

Keyword(s):

Severe Acute Respiratory Syndrome ◽

Antibody Titer ◽

Healthcare Workers ◽

Vaccination Strategy ◽

Antibody Assay ◽

Serum Samples ◽

Vaccination Strategies ◽

Antibody Assays ◽

Antibody Titers ◽

Dose Scheme

We investigated the longevity rates of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after a complete ChAdOx1 nCoV-19 vaccination, which are rare and important to estimate their efficacy and establish a vaccination strategy. We assessed the positivity rates and changes of titers before (T0) and at one month (T1), four months (T2), and seven months (T3) after a ChAdOx1 nCoV-19 vaccination using five SARS-CoV-2 antibody assays. A total of 874 serum samples were obtained from 228 (T0 and T1), 218 (T2), and 200 (T3) healthcare workers. The positive rates for all five assays were 0.0–0.9% at T0, 66.2–92.5% at T1, 98.2–100.0% at T2, and 66.0–100.0% at T3. The positive rates at T3 were decreased compared to those at T2. The median antibody titers of all the assays at T3 were significantly decreased compared to those at T2 (860.5 to 232.0 U/mL for Roche total, 1041.5 to 325.5 AU/mL for Abbott IgG, 10.9 to 2.3 index for Siemens IgG, 99.5% to 94.7% for SD Biosensor V1, and 88.5% to 38.2% for GenScript). A third-dose scheme can be considered based on our data generated from five representative assays. Our findings contribute insights into SARS-CoV-2 antibody assays and appropriate vaccination strategies.

Download Full-text

Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care

10.1101/2021.01.28.21250664 ◽

2021 ◽

Author(s):

Susanna Klevebro ◽

Fuad Bahram ◽

K. Miriam Elfström ◽

Ulrika Hellberg ◽

Sophia Hober ◽

...

Keyword(s):

Intensive Care Unit ◽

Intensive Care ◽

Severe Acute Respiratory Syndrome ◽

Emergency Care ◽

Healthcare Workers ◽

Care Hospital ◽

Patient Contact ◽

Questionnaire Data ◽

Igg Antibodies ◽

Serum Samples

AbstractAimWe aimed to assess the risk for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in a large cohort of healthcare workers (HCWs).MethodsFrom May 11 until June 11, 2020, 3,981 HCWs at a large Swedish Emergency Care hospital provided serum samples and questionnaire data. Exposure was measured by assaying IgG antibodies to SARS-CoV-2.ResultsThe total seroprevalence was 17.7% and increased during the study period. Among the seropositive HCWs, 10.5% had been entirely asymptomatic. Participants who worked with COVID-19 patients had higher odds for seropositivity: ORadj 1.96 (95% CI 1.59 – 2.42). HCWs from three of the departments managing COVID-19 patients had significantly higher seroprevalences, whereas the prevalence among HCWs from the Intensive Care Unit (also managing COVID-19 patients) was significantly lower.ConclusionHCWs in contact with SARS-CoV-2 infected patients had a variable, but on average higher, likelihood for SARS-CoV-2 infections.

Download Full-text

Immunoglobulin (Ig)A seropositivity against SARS-CoV-2 in healthcare workers in Israel, 4 April to 13 July 2020: an observational study

Eurosurveillance ◽

10.2807/1560-7917.es.2021.26.48.2001690 ◽

2021 ◽

Vol 26 (48) ◽

Author(s):

Yaniv Lustig ◽

Carmit Cohen ◽

Asaf Biber ◽

Hanaa Jaber ◽

Yael Becker Ilany ◽

...

Keyword(s):

Healthcare Workers ◽

Significant Risk ◽

Igg Antibodies ◽

Exposure Risk ◽

Serum Samples ◽

Igg Antibody ◽

High Exposure ◽

Iga Antibodies ◽

Iga Response ◽

Antibody Elisa

Introduction The COVID-19 pandemic has put healthcare workers (HCW) at significant risk. Presence of antibodies can confirm prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Aim This study investigates the prevalence of IgA and IgG antibodies against SARS-CoV-2 in HCW. Methods Performance of IgA and IgG antibody ELISA assays were initially evaluated in positive and negative SARS-CoV-2 serum samples. IgA and IgG antibodies against SARS-CoV-2 were measured in 428 asymptomatic HCW. We assessed the risk of two groups: HCW with high exposure risk outside work (HROW) residing in areas where COVID-19 was endemic (n = 162) and HCW with high exposure risk at work (HRAW) in a COVID-19 intensive care unit (ICU) (n = 97). Results Sensitivities of 80% and 81.2% and specificities of 97.2% and 98% were observed for IgA and IgG antibodies, respectively. Of the 428 HCW, three were positive for IgG and 27 for IgA. Only 3/27 (11%) IgA-positive HCW had IgG antibodies compared with 50/62 (81%) in a group of previous SARS-CoV-2-PCR-positive individuals. Consecutive samples from IgA-positive HCW demonstrated IgA persistence 18–83 days in 12/20 samples and IgG seroconversion in 1/20 samples. IgA antibodies were present in 8.6% of HROW and 2% of HRAW. Conclusions SARS-CoV-2 exposure may lead to asymptomatic transient IgA response without IgG seroconversion. The significance of these findings needs further study. Out of work exposure is a possible risk of SARS-CoV-2 infection in HCW and infection in HCW can be controlled if adequate protective equipment is implemented.

Download Full-text

High Levels of Plasma Protein C in Nephrotic Syndrome

Thrombosis and Haemostasis ◽

10.1055/s-0038-1661225 ◽

1985 ◽

Vol 53 (01) ◽

pp. 005-007 ◽

Cited By ~ 16

Author(s):

I Pabinger-Fasching ◽

K Lechner ◽

H Niessner ◽

P Schmidt ◽

E Balzar ◽

...

Keyword(s):

Nephrotic Syndrome ◽

Plasma Protein ◽

Protein C ◽

Inverse Correlation ◽

Elevated Plasma ◽

Significant Inverse Correlation ◽

At Iii ◽

Thrombotic Tendency ◽

Protein C Activity

SummaryIn patients with severe nephrotic syndrome determinations of plasma protein C : Ag levels (8 patients: 5 adults, 3 children) and protein C activity (3 out of 8 patients) revealed significantly elevated plasma protein C concentrations. Furthermore we observed a significant inverse correlation of protein C : Ag to AT III : Ag levels. No protein C : Ag could be detected in the urine of two patients studied. We conclude from our data, that changes of plasma protein C do not contribute to the high thrombotic tendency in nephrotic syndrome.

Download Full-text